Published in Gene Therapy Weekly, July 31st, 2003
Researchers at the U.S. Food and Drug Administration have taken advantage of the ligand binding and internalization properties of interleukin-13 receptor (IL-13R)alpha2 to make pancreatic tumor cells more susceptible to the cytotoxic effects of recombinant IL-13. In addition to killing tumors directly, the therapy may activate a tumor immune response, study authors say.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.